Thomas Fuchs

Thomas Fuchs is the current CEO at Cimeio Therapeutics. Thomas has held various positions at genentech, including vice president, market analysis and strategy; senior director, sales and marketing, skin cancer franchise; and life cycle leader, venclexta. Thomas also worked as a division manager for the hepatology franchise and as a marketing director for the hematology franchise. Prior to joining genentech, they worked for merck as part of their MBA rotation program.

Thomas Fuchs has a master of business administration from Northwestern University - Kellogg School of Management, a masters from St. Mary's University, and a bachelors in business administration from the University of Wisconsin - Stout.

Some individuals on their team include Stefanie Urlinger - SVP, Biology, Lukas Jeker - Founder, SVP Gene Editing, and Thomas Winkler - Chief Medical Officer.